Background Gonadotropin-inhibitory hormone (GnIH, human homologue of RFRP-3) suppresses gonadotropin secretion in animal models, but its effects have not been studied in the human. Objective We tested the hypotheses that exogenous GnIH inhibits LH secretion (i) in postmenopausal women and (ii) in men concurrently administered exogenous kisspeptin. Design Following in vitro and in vivo preclinical studies to functionally characterize the GnIH peptide, a dose-finding study (human GnIH: 1Á5-150 lg/kg/h, iv for 3 h) was undertaken, and 50 lg/kg/h selected for further evaluation. Five postmenopausal women were administered 50 lg/kg/h iv infusion for 3 h or vehicle on two separate days. Four men were administered kisspeptin-10 (0Á3 lg/kg iv bolus) with simultaneous infusion of GnIH (50 lg/kg/h, iv for 3 h) or vehicle. Participants Healthy postmenopausal women (mean age 58 AE 2 years, LH: 30Á8 AE 2Á9 IU/l, FSH: 78Á7 AE 6Á4 IU/l, oestradiol: <50 pmol/l) and men (39Á8 AE 2Á1 years, mean total testosterone 12Á1 AE 1Á8 nmol/l, LH 2Á2 AE 0Á2 IU/l). Primary outcome Change in area under curve (AUC) of LH during GnIH vs vehicle. Results During GnIH administration in postmenopausal women, LH secretion decreased (DAUC: À9Á9 AE 1Á8 IU/3 h) vs vehicle (DAUC: À0Á5 AE 1Á7 IU/3 h; P = 0Á02). Kisspeptin-10-stimulated LH responses in men were not affected by GnIH co-administration (60-min AUC of LH 6Á2 AE 0Á8 IU/h with kisspeptin-10 alone, 6Á3 AE 1Á0 IU/h, kisspeptin-10 with GnIH, P = 0Á72). Exogenous GnIH was well tolerated, with no adverse events reported. Conclusions Gonadotropin-inhibitory hormone decreased LH secretion in postmenopausal women in this first-in-human
Introduction
Pulsatile secretion of gonadotropin-releasing hormone (GnRH) stimulates the secretion of gonadotropins (LH and FSH) and the downstream secretion of gonadal steroid hormones. [1] [2] [3] Gonadotropin-inhibitory hormone (GnIH) is a hypothalamic neuropeptide initially discovered in birds as an inhibitor of LH secretion, 4 but its activity has not been studied in humans. We report the first human studies on the effect of exogenous GnIH on LH secretion. The avian GnIH peptide (SIKPSAYLPLRF-NH 2 ) has one human homologue which is inactive and two orthologues which have the characteristic carboxyl terminal RF-amide. RFRP-1 (MPHSFANLPLRF-NH 2 ) and RFRP-3 (VPNLPQRF-NH 2, ) were isolated and structurally identified in the human hypothalamus. 5 GnIH inhibits GnRH-stimulated mobilization of intracellular calcium in avian, 4 ovine 6 and bovine 7 gonadotrophes in vitrosuggesting a pituitary locus of action. These data, and other evidence from a range of species, 5, [8] [9] [10] [11] [12] [13] [14] reviewed recently elsewhere, 15 indicate that GnIH is a specific inhibitor of gonadotropin secretion in mammals, signalling through the GnIH receptor (GnIH-R, GPR147) via inhibition of cyclic AMP production. GnIH neurons display close apposition to GnRH neurons in sheep, 16 nonhuman primate 17 and human 5 hypothalami, suggesting that GnIH may also directly regulate GnRH secretion. Following preclinical studies to characterize the activity of the GnIH peptide in vitro and in the ovariectomized ewe, we investigated the effect of GnIH on LH secretion in two human models of increased GnRH secretion: in postmenopausal women and in healthy men administered exogenous kisspeptin.
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Methods

GMP kisspeptin and GnIH
Kisspeptin-10 and GnIH peptides were custom synthesized to GMP standards (Bachem GmBH, Weil am Rhein, Germany). Purity was assessed by HPLC at 97% with a mass balance of 98Á8%. Both peptides were made up within the hour before injection/infusion by diluting 1 mg of lyophilized peptide in 5 ml sterile normal saline. The bolus dose of kisspeptin-10 (0Á3 lg/kg) was selected for acute LH stimulation tests based on our previous dose-finding study of kisspeptin-10 18 and other published data.
3
Characterization of GnIH in vitro
The objective of these in vitro studies was to compare the biological activity of the custom-synthesized GnIH peptide used in this study with that of GnIH previously used in published data involving nonhuman species. Whole-cell receptor binding and CREluciferase assays were carried out in parallel using the customsynthesized GMP GnIH and a custom-synthesized preparation (EzBiolab, Carmel, IN, USA) used extensively by our laboratory.
Whole-cell receptor binding assay. The methods are described in detail elsewhere, 19 but in brief, COS-7 cells were electroporated with 10 lg NPFFR1 (GPR147) and seeded in 12-well plates. Forty-8 h posttransfection cells were incubated in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-Dulbecco's modified Eagle's medium (DMEM) with 100 000 cpm 125 I radiolabelled-RFRP3/well and increasing concentrations of nonradiolabelled peptide in the range of 0-1 lM for 4 h at 4°C. Cells were then rapidly washed twice with cold phosphate-buffered saline (PBS; +MgCl2/CaCl2). Thereafter, 0Á5 ml 0Á1 M NaOH was added to the cells and incubated at room temperature for 15 min to lyse the cells. Cell lysates were transferred to plastic tubes and bound radioactivity counted with a Berthold LB2111 gamma counter for 1 min.
CRE-Luciferase assay. HEK 293T cells were seeded in 24-well plates coated with Matrigel (BD Biosciences). The next day, cells were chemically transfected [X-tremeGENE HP DNA Transfection Reagent (Roche)] with GPR147 and CRE-Luc reporter gene plasmid DNA in a 1:1 DNA ratio. Plates were incubated for 24 h posttransfection and then washed twice with PBS+. Thereafter, starving media (DMEM, 1% pen/strep, 4 mM L-glutamine, 10 mM HEPES) was added to the cells overnight. Media was aspirated and replaced 0Á5 ml of compound dilutions prepared in starving media. Plates were incubated for 6 h at 37°C after which they were transferred to ice and washed with cold PBS+. Diluted passive lysis buffer (20 ll) was added to each well and plates placed on a shaker at 1050 rpm for 15 min at room temperature. Lysates were diluted 1:4, and 20 ll was transferred to a white, flat-bottomed 96-well plate. Luciferase activity was measured for 10 s on a Lumat LB9501 Luminometer after 100 ll LARII was added to each well.
LH inhibition by GnIH in ewes
Animals and peptide infusion regime. Groups of four ovariectomized ewes were held in single pens, and both jugular veins were cannulated on the day prior to experimentation to allow blood sampling and infusion. Venous blood samples were taken at 10-min intervals for 7Á5 h, in 2Á5-h blocks, before, during and after infusion of either GnIH or vehicle (saline). The animals received a loading dose of 1 mg and then an infusion of 1 mg/h, using an infusion rate of 1 ml/h. All ovine experiments were carried out at the University of Monash (IJC) in compliance with regulations and ethical standards.
Radioimmunoassay of ovine LH. LH in plasma was measured as previously described 20 using NIH-oLH-S18 as the standard and NIDDK-anti-oLH-I as the antiserum. Iodinated ovine LH (125 I-NIDDK-AFD-9598B) was used as tracer. Assay sensitivity was 0Á1 ng/ml. Intra-assay coefficient of variation (CV) was <10% between 0Á6 and 13Á7 ng/ml, and interassay CV was 7Á8% at 10Á4 ng/ml and 9Á5% at 20Á3 ng/ml.
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LH Pulse analysis in ovine studies. An LH pulse was defined as having occurred when the assay value of a given sample exceeded the assay value of the previous sample by at least three standard deviations, as well as other criteria detailed previously, 22 using error estimates generated by the computer program of Salamonsen et al. 23 Comparisons of LH pulse amplitude, interpulse interval and mean LH between groups infused with GnIH and vehicle were made using two-way ANOVA.
Human studies
Participants. Five healthy postmenopausal women (mean age: 58 AE 2 years, 12Á4 AE 2Á6 years since last menstrual period, LH: 30Á8 AE 2Á9 IU/l, FSH: 78Á7 AE 6Á4 IU/l, oestradiol: <50 pmol/l) and four healthy adult men (mean age 39Á8 AE 2Á1 years, total testosterone 12Á1 AE 1Á8 nmol/l, LH 2Á2 AE 0Á2 IU/l and FSH 4Á8 AE 12 IU/l took part in the study. LH, FSH and testosterone were all within normal range in the men, and this was confirmed on at least one additional morning sample). Baseline physical examination, full blood count, renal function, liver function and serum electrolytes were within normal limits. All volunteers provided written informed consent to take part in this study, which was approved by the South East Scotland Research Ethics Committee (10/S1101/53). The study was also approved by the Edinburgh Clinical Research Facility Phase 1 and First-in-Human Study Review Committee (Ref E10903) .
Peptide infusion protocols for human studies. First, we set to establish a safe and effective dose that achieved nanomolar concentrations of RFRP3 in the peripheral circulation when administered as an intravenous infusion in two postmenopausal women (dose-finding study). Second, the effects of the maximally effective dose (identified from the dose-finding study as approximately 50 lg/kg/h) was studied in three additional postmenopausal women, to give a total n = 5 for this dose. Third, four healthy men were given intravenous boluses of kisspeptin in the presence or absence of GnIH 50 lg/kg/h administered concurrently as intravenous infusion (Kisspeptin-GnIH Study).
Effects of GnIH on LH in postmenopausal women
(a) Dose-finding study. The median inhibitory concentration of GnIH at its cognate receptor (GPR147) is 1-2 nM. 24 The objective of this study was therefore to identify a dose at which circulating GnIH concentrations >1 nM were achieved. Two healthy postmenopausal women were admitted six times to our clinical research facility, with a minimum intervisit interval of a week. Each of these visits involved 6 h of frequent (every 10-min) venous blood sampling to assess effects on LH secretion. After 3 h of baseline sampling, an infusion of GnIH (1Á5, 5, 15, 50 and 150 lg/kg/h) or vehicle (normal saline) was administered for a further 3 h. At the start of this infusion, an intravenous bolus of GnIH (25% of hourly infusion dose) or vehicle was administered, simulating the studies in which GnIH was effective in ovariectomized ewes. For safety reasons, doses were administered in increasing order in an unblinded manner under medical supervision and participants were observed in the research facility for at least an hour after the infusion completed. LH sampling was opportunistically continued at 10-min interval during this additional hour of safety monitoring.
In addition to collection of serum for hormone assays, plasma samples were collected immediately before as well as at regular intervals up to 4 h (at 30, 60, 120, 150, 179, 190, 200, 210, 220, 230 and 240 min) after commencing the infusion for pharmacokinetic assessment to quantify circulating GnIH. GnIH concentrations were estimated using liquid chromatography-tandem mass spectrometry. A DPP-IV inhibitor (Diprotin A, 0Á1 mM final concentration; Sigma I9759; St. Louis, MO, USA) and protease inhibitor cocktail (Sigma P8340, 91 final concentration; both sourced from Sigma-Aldrich) were added to these samples to inhibit breakdown of GnIH after serum collection.
Blood pressure, pulse rate and peripheral oxygen saturations were measured with standard automated techniques. Full blood count, serum electrolytes, liver and renal function were checked at the beginning and end of each visit.
(b) Effects of 50 lg/kg/h intravenous GnIH in postmenopausal women. In addition to the two women who participated in dose-finding study, three more healthy postmenopausal women received 50 lg/kg/h intravenous infusions of GnIH (with a 12Á5 lg/kg intravenous bolus at the start of the infusion) and vehicle for 3 h each on two separate days, at least a week apart, using the LH sampling protocol outlined above.
LH pulsatility in all five women during the 50 lg/kg/h of GnIH was compared with the pulsatility observed during the infusion of vehicle.
Effects of GnIH on kisspeptin-10 stimulation of LH in healthy men
The objective of this study was to test the hypothesis that coadministration of GnIH would attenuate the stimulatory LH response elicited by kisspeptin.
Healthy male volunteers (n = 4) were admitted twice to our clinical research facility for 7Á5 h, and LH samples obtained at 10-min intervals. Two intravenous boluses of kisspeptin-10 (0Á3 lg/kg, 23 pmol/kg) were administered at 60 min and 270 min. On the first visit, an intravenous infusion of saline was started at 240 min. On the second visit, a 50 lg/kg/h intravenous infusion of GnIH was commenced at the identical time point (240 min) to that of vehicle infusion, along with a 12Á5 lg/kg intravenous bolus of GnIH administered at the start of this infusion which continued for 180 min. This protocol is identical to the 50 lg/kg/h infusion protocol used in the dosefinding and replication studies described above.
Human LH pulsatility analysis and statistical comparisons. Blood samples were centrifuged immediately at 4°C for 10 min at 3000 rpm and serum frozen at À20°C until analysis. LH was determined by ELISA as previously described. 18 Interassay coefficient of variation for all hormonal assays was <5% at the concentrations measured. Intra-assay coefficient of variation of LH was 2Á9%. All samples from each of the study visits were analysed together. Area under curve (AUC) of LH was calculated using trapezoid integration. In studies to assess the impact of exogenous GnIH on LH secretion, 180-min AUC before and during the infusion of GnIH were calculated to derive DAUC LH -the arithmetic difference of AUC over 3 h before and during the infusion. Paired Student's t tests were used to compare DAUC LH during vehicle and GnIH infusions.
In the kisspeptin-GnIH study, 60-min AUC was calculated during three periods: baseline (first hour of the study) and 60 min after each of the kisspeptin-10 boluses. Repeated-measures ANOVA was used to assess variance in 60-min AUC and multiple comparisons made using Fisher's least-significant difference (LSD) test. We have previously shown the sensitivity of this approach to detect LH response to kisspeptin-10. 18, 25, 26 LH pulses were identified, and mass-per-pulse (MPP) and basal LH secretion were calculated using a deconvolution algorithm using cluster analysis with 93% sensitivity and specificity on blinded data. 27 Paired Student's t-test was used to assess changes in pulse frequency, MPP and basal LH secretion. Data are presented as mean AE SEM. A two-sided P < 0Á05 was regarded as statistically significant for all analyses. The statistical software package Graphpad Prism 6 for Mac OSX (Graphpad, La Jolla, CA 92037, USA) was used.
Results
In vitro studies GMP custom-synthesized GnIH (Bachem) and comparator peptide (EZbiolab) induced an inhibition of forskolin-induced accumulation of cAMP with similar potencies (Figure S1 ). Both peptides also displayed high affinity for the receptor with no statistically significant difference in the IC50 (data not shown).
In summary, the GnIH peptide used in the present human study thus has identical binding and signalling characteristics to a peptide preparation previously used in nonhuman studies at the GPR147 receptor.
LH Inhibition by GnIH in Ewes
Infusion of GnIH significantly reduced the amplitude of LH pulses in ovariectomized ewes ( Figure S2 ). LH pulse amplitude decreased from 0Á9 AE 0Á1 ng/ml before the GnIH infusion to 0Á4 AE 0 ng/ml during it (P < 0Á002) and returned to baseline (0Á7 AE 0Á1 ng/ml) following discontinuation. In the control vehicle infusion group, LH pulse amplitude remained unchanged at 1 AE 0Á1 ng/ml before, 1Á3 AE 0Á2 ng/ml during and 1Á3 AE 0Á3 ng/ml after infusion.
There were no significant changes in LH pulse frequency or mean LH during either GnIH or vehicle infusions. GnIH-infused sheep had 3Á8 AE 0Á25 pulses before, 4Á0 AE 0 pulses during the infusion and 4Á0 AE 0Á4 pulses in the postinfusion study period. Control animals infused with vehicle were observed to have 3Á5 AE 0Á5, 3Á75 AE 0Á25 and 3Á75 AE 0Á5 pulses during corresponding sampling windows.
Individual animal-level data on LH secretion in both GnIHand vehicle-treated groups are tabulated in Table S1 .
Effects of GnIH on LH in postmenopausal women
Dose-finding study. All doses of GnIH were well tolerated, with no adverse events. Both women showed modest but dosedependant suppression of LH secretion during GnIH infusion. One subject achieved maximal reduction in AUC of LH at 15 lg/kg/h dose (DAUC: À9Á7 IU/l/3 h) and the other at 50 lg/ kg/h (DAUC: À10Á9 IU/l/3 h; Fig. 1a) .
During infusion of 50 lg/kg/h, circulating concentrations of GnIH rose from below the limits of quantification (1 ng/ml) before administration to 2Á4 AE 0Á4 ng/ml during the infusion (range: 1Á2-3Á8 ng/ml; 1Á2-3Á9 nM) and 6Á5 AE 1Á8 ng/ml (range: 1Á9-11Á9 ng/ml; 2-12Á3 nM) in the two women. GnIH became undetectable 10 min after the end of the infusion.
The highest of the doses studied (150 lg/kg/h) resulted in higher plasma concentrations of GnIH (10Á1 AE 1Á5 ng/ml; 10Á4 AE 1Á5 nM) and (11Á1 AE 2Á5 ng/ml; 11Á5 AE 2Á6 nM) in the two subjects. However, this increase in circulating peptide concentration was not associated with larger reductions in LH secretion than that observed with the 50 lg/kg/h dose. Therefore, the lowest dose that achieved nanomolar concentrations in peripheral circulation, that is 50 lg/kg/h, was selected for further studies.
LH inhibition by GnIH in postmenopausal women
Gonadotropin-inhibitory hormone infusion (50 lg/kg/h) significantly decreased LH secretion (DAUC: À9Á9 AE 1Á8 IU/3 h) when compared to the infusion of vehicle (DAUC: À0Á5 AE 1Á7 IU/3 h) in the five women (P = 0Á02, Fig. 1b) . Decreases in mean LH were observed in four of the five women studied. Individual volunteer-level data on mean LH secretion before, during and after saline and GnIH treatments are tabulated in Table S2 .
There was no effect on pulsatile LH secretion (Fig. 2) . Baseline pulse frequency of 0Á8 AE 0Á1 pulse/h remained unchanged during GnIH treatment, at 0Á8 AE 0Á1 pulse/h. Nevertheless, MPP showed a numerical increase, from 20Á2 AE 4Á5 IU/l at baseline to 27Á8 AE 6Á4 IU/l during GnIH infusion (P = 0Á052). Consistent with these, the total pulsatile secretion of LH also showed a numerical increase without statistical significance -at 100Á6 AE 26Á6 IU/l/3 h at baseline to 139Á1 AE 38Á2 IU/l/3 h (P = 0Á124) during GnIH infusion.
Co-administration of GnIH and kisspeptin-10 in men
Kisspeptin-10 bolus (0Á3 lg/kg iv) significantly increased LH secretion, with 60-min AUC of LH increasing from 2Á8 AE 0Á8 IU/l/h to 6Á5 AE 0Á9 after each of the two boluses in the control visit (ANOVA P = 0Á005, Fisher's LSD P = 0Á003, baseline vs kisspeptin boluses; 0Á96 (comparing the two kisspeptin boluses; Fig. 3a ). During concurrent administration of GnIH, both boluses of kisspeptin-10 also elicited significant increases in LH secretion, with 60-min AUC of LH increasing from 3Á1 AE 0Á5 IU/l/h to 6Á2 AE 0Á8 IU/l/h with kisspeptin-10 alone vs 6Á3 AE 1Á0 IU/l/h with kisspeptin-10 in the presence of GnIH, respectively (Fisher's LSD P < 0Á005). There was no statistical difference between responses to the two kisspeptin-10 boluses administered before or during GnIH infusion (Fisher's LSD P = 0Á715), Fig. 3b . Individual volunteer-level 60-min AUC during baseline and after the two kisspeptin-10 boluses are tabulated in Table S3 . Figure 4 provides exemplar LH profiles from a participant during GnIH and vehicle infusion visits.
Safety of GnIH
Gonadotropin-inhibitory hormone infusions were well tolerated with no serious adverse events reported. Heart rate and blood pressure, which were monitored intensely during study visits, showed no significant change. Serum electrolytes, renal function, full blood count and liver function monitored at all study visits also remained unchanged.
Discussion
The present study provides first-in-human data on the effects of exogenous GnIH effects on LH secretion in women and men, in paradigms of increased GnRH secretion. In postmenopausal women, GnIH administration resulted in a modest suppression of LH secretion, while it did not affect kisspeptin-stimulated LH secretion in men. GnIH was well tolerated by men and women who took part in this first-in-man study, providing reassurance about its safety for future clinical studies.
Infusions of GnIH (up to the dose of 150 lg/kg/h in two postmenopausal women, 50 lg/kg/h in all other men and women) for 3 h were well tolerated. Serum concentrations in the low nanomolar range were achieved with continuous intravenous infusion of GnIH at 50 lg/kg/h and associated with significant decrease in LH secretion (AUC of LH) in postmenopausal women. We demonstrated that the circulating concentrations of 1Á2-12Á3 nM/l achieved are sufficient to bind to the GPR147 receptor and inhibit forskolin-stimulated cAMP generation (Fig. 1) .
Our results are consistent with decreased LH secretion observed in large animal models (ewes and calves) exposed to GnIH. 6, 7 In rodents, the effects of GnIH appear to show sexual dimorphism. Male rats 9, 14 and hamsters 8 respond with gonadotropin suppression, while female rats showed no change in LH or FSH when the peptide was administered intracerebroventricularly. 28 The pattern of reduction in LH secretion observed in postmenopausal women in our study during GnIH administration appears to be broadly concordant with that observed in previously published ovine 6 and bovine models. 7 Postmenopausal women in the present study showed no change in LH pulse frequency; the corresponding ovine model (ovariectomized sheep) also showed no reduction in pulse frequency in the present study as well as in previous studies. 6 A previous study using a bovine model did show a reduction in pulse frequency, 7 but in that study, GnIH was administered as multiple boluses rather than by infusion. Furthermore, the bovine models used were castrated males, which do not allow direct comparison with the data in the present study.
The magnitude of reduction of LH in human volunteers in the present study appears to be lower than the marked reduction in serum LH observed in ovariectomized sheep. 6 There is considerable interspecies difference in the effects of GnIH, 29 which may explain some of the differences. Therefore, the most parsimonious explanation for the differential responses in ovine models and human volunteers is potential interspecies variability. Furthermore, as our study was based only on a small number of participants, the true effect size of LH response to GnIH in a wider population cannot be reliably extrapolated. In addition, administration of exogenous peptide hormones, that is the experimental paradigm employed here, is not an appropriate technique to study the physiological role of the peptide. However, even when taking study limitations into consideration, the limited suppression of LH observed in the present study suggests that pharmacological application of GnIH (or its agonists) in human disorders of excess LH secretion may not be feasible. Gonadotropin-inhibitory hormone had no effect on kisspeptin-stimulated LH secretion in men in the present study where 50 lg/kg/h was administered as continuous intravenous infusion. In addition to its main objectives, the present study also assessed the effects of repeated doses of kisspeptin-10 boluses within the same individual -four boluses on two separate study days. These data showed that there was remarkable intra-individual consistency in LH response to kisspeptin-10 (Table S3 ). This is distinct from the tachyphylaxis observed on repeated dosing of kisspeptin-54 3 or with longer-acting kisspeptin analogues. 30 This finding could lend support for the continuing development of kisspeptin-10 as a physiological probe to ascertain GnRH function in or as a potential therapeutic option to stimulate GnRH endogenously. 3 We chose kisspeptin-10 administration as a model of LH stimulation to study the effects of GnIH on LH secretion in men. Kisspeptin acts via endogenous GnRH secretion and results in a doubling in peripheral LH concentrations, comparable to an endogenous LH pulse, and is thus a more physiologically relevant stimulus than exogenous GnRH, which elicits around a 10-fold rise in LH. 3 Furthermore, we have previously shown that the acute LH response to kisspeptin in men is not affected by prevailing sex-steroid status. 25 LH response to kisspeptin remained unchanged with concurrent administration of GnIH.
With the limited LH suppression observed in these first-inman studies in both men and women, it is reasonable to speculate that the role of GnIH in the regulation of LH secretion in the human may be less robust than in other species. Nevertheless, these studies have limitations. As a first-in-human study with associated safety considerations, the exposure to human volunteers in the study was limited to 3 h and only a small number of volunteers were studied. Furthermore, we did not undertake a separate dose-finding study in men, but have assumed similar pharmacokinetics in men and women.
Gonadotropin-inhibitory hormone-induced gonadotropin subunit gene transcription is suppressed by GnIH orthologues by inhibiting adenylate cyclase/cAMP/protein kinase A-dependent ERK activation. 31 This transcriptional effect suggests that a longer-exposure paradigm may have achieved greater suppression of LH secretion. However, the rapid clearance of GnIH from circulation observed here makes it challenging to deliver sufficient quantities of the native peptide intravenously to maintain stable serum concentrations over long durations. This challenge has been effectively overcome for GnRH and other small peptide hormones by incorporation of D-amino acids to reduce proteolytic degradation and by formulating in biodegradable polymers which can deliver efficacious levels of peptide for up to 1 year. Therapeutic potential of GnIH to treat disorders characterized by increased LH secretion (e.g. PCOS, menopausal hot flushes, precocious puberty) needs to be assessed in context of emerging data on kisspeptin and neurokinin B modulation. Prima facie, GnIH appears to be a less potent tool in comparison with these approaches. 3, 32 In conclusion, in this first-in-human study, we have demonstrated that exogenously administered GnIH has a suppressive effect on LH secretion in postmenopausal women and that kisspeptin-10-mediated LH secretion in men is unaffected during concomitant administration of GnIH. Further studies are required to fully elucidate the physiological mechanisms and the therapeutic potential for GnIH.
